Acadia CEO on NIH Cuts, Biotech Innovation, and Rare Disease Therapies

Investing in Neuroscience and Rare Diseases

• 💡 Neuroscience and rare diseases are investable due to significant unmet medical needs in areas like Alzheimer's, dementia, and conditions lacking therapies.
• 🚀 Acadia Pharmaceuticals focuses on bringing innovation to patients in these underserved areas.

Impact of NIH Funding Cuts

• ⚠️ While Acadia's pipeline is not currently disrupted, the CEO expresses concern about the long-term effects of NIH cuts on early-stage innovation.
• 🧠 Smaller biotechs, which often rely on academic research for initial breakthroughs, are particularly vulnerable to these funding reductions.

Policy and Advocacy in Biotech

• 🗣️ Acadia actively engages with policymakers through organizations like BIO to ensure the voice of small and midsize biotech is heard.
• 🎯 The focus is on advocating for policies that support innovation, particularly for rare diseases, rather than a broad, one-size-fits-all approach.
• ⚖️ The CEO emphasizes that while cost pressures are real, policies should be thoughtfully developed to avoid unintended consequences for future drug development.

Affordability and Patient Support

• 🤝 Acadia prioritizes patient support services, offering financial assistance and guidance through insurance and treatment processes.
• 💬 Two-way communication with patient advocacy organizations is crucial for understanding community needs and developing new formulations, as seen with their work on debut.
• ✅ The company strives to ensure that rare disease therapies are accessible to patients, working closely with patient groups to address needs.